Maternal Microchimerism in Lymph Nodes of Infants With Biliary Atresia at Time of Kasai's Operation (K-LNMC)

November 14, 2014 updated by: Carsten Engelmann, Medizinische Hochschule Brandenburg Theodor Fontane

Search for Maternal Microchimerism in Swollen Portal Lymph Nodes of Infants With Biliary Atresia.

Maternal microchimerism has been discussed as an etiological mechanism in infantile (perinatal) biliary atresia (BA). In Kasai's operation (resection of the liver hilum plaque followed by hepato-portoenterostomy) surgeons frequently encounter swollen portal and mesenteric lymph nodes.

Lymph nodes were sampled during Kasai' s operation and examined for maternal DNA.

Study Overview

Status

Completed

Conditions

Detailed Description

Upon operation of infants with non-syndromatic biliary atresia (BA, commonest form), surgeons almost invariably note the prominent finding of multiple swollen lymph nodes of up to 2 cm in size in the porta hepatis and the small bowel mesentery where they may constitute grape like complexes. Same-age infants laparotomized for other pathology commonly do not present such nodes.

Biliary atresia is a disease of the newborn which is fatal when left untreated. Histologically it corresponds to a degeneration of intra- und extra hepatic bile ducts within a in part specific inflammatory infiltrate and progressive cirrhosis.

The etiology of this rare but constant disease (1:8-1:15.000) is unknown. Currently in BA etiology research two main avenues are pursued:

  1. Virally induced perinatal (auto)immune processes are suspected. An experimental form of BA can be provoked by infecting murine mothers with dsRNA-viruses e.g. Rhesus-rotaviruses or Reo-viruses while in mice, vaccination of mothers has prevented experimental BA . The importance of the γ/δ-T-cell and IL17/IL 23 pathway , for BA is currently probed. However, in groups of syngenic animals treated by the same batch of viruses BA tends to be inconstant and it is limited to extrahepatic bile ducts such as about the validity of the animal model is an issue.
  2. The other direction of research does not primarily rely on experiments involving newborn animals: There are indications that during pregnancy the placental barrier may become permeable for maternal lymphocytes (e.g. by a faulty silencing of T-cell attracting chemokines in decidual stroma cells) and already in 2008 maternal lymphocytes have been demonstrated in livers of BA infants . Subsequently the phenomenon of materno-fetal microchimerism has come into focus of BA ethiology research: in the context of mixed materno-fetal immune reactions cells of maternal origin could misdirect the immature immune system of the infant into auto-immunity or act directly as effectors in a graft vs. host like fashion.

The importance of mesenteric and portal lymph nodes for maturation of the immune system during pregnancy has been reported recently . Moreover it has been demonstrated that flow the between liver and portal lymph nodes is bidirectional . In In mice the frequence of CD4+ and FoxP3+ regulatory T-cells was found to be linked to the mothers immune status. We thus hypothesized that the prominently swollen lymph nodes of BA infants which surgeons constantly encounter during Kasai's operation may hold a key to the better understanding of pathophysiological important lymphocyte trafficking mechanisms.

In the standard operation, the Kasai-operation which in a race with increasing liver cirrhosis makes sense up to an age of 4 months, the degraded rests of the major bile ducts in the liver hilus (the so called "hilar plate") are resected, A Roux y-loop is sutured onto the resection site. It shall drain any contingent bile flow from remaining bile ducts. The long term success rate of this tentative of surgical cure which is of moderate technical complexity and invasiveness is estimated to ca. 15-20%. In the remaining a partly sucess may postpone the necessity of liver transplantation. We examined in seven consecutive patients with histologically proven biliary atresia whether in periportal lymph nodes there was evidence for maternal gentic material.

Methods :

7 consecutive patients with the preoperative diagnosis of BA were included in the study. Other causes of icterus prolongatus (α1 anti-trypsin deficiency, Alagilles syndrom, PFIC etc.) had been excluded amongst the methods technical successful ERCP (5/7 patients) which showed absence of intrahepatic bile ducts.

After obtaining the parent's informed consent 2 ml EDTA whole blood were collected from mother and infant. During Kasai's operation one portal and one mesenterial lymphnode were sampled (Hannover Medical School ethical committee vote No.1650/11.12.2012. After bipolar dissection the mesenteric gaps were closed with 4-0 Vicryl sutures.

Lymph nodes were disrupted mechanically and DNA was extracted enzymatically (QIAmp Kit, Qiagen, Hilden/Germany) as described previously and normalized to 30 ug/ml.

Short tandem repeat analysis was realized with multiplex PCR for markers LIPOL, VWA, TH01, D19S253, CSF, PLA2A. FGA, D21S11, D18S51 as described. Briefly, fragment length analysis was performed an Abi Prism 310 System with GeneScan 3.11. software for comparison of mother's and infant's blood with lymph node DNA.

Genetic single nucleotide polymorphisms (SNPs) were traced by quantitative real time PCR chimerism analyses. Reactions were executed on an iCycler iQ5 real-time PCR platform (Bio-Rad) using the ABsolute QPCR Rox Mix (Thermo scientific). Custom designed primers and probes were provided by Sigma-Aldrich. Control reactions and normalization of sample DNA were performed by amplifying the albumin gene.

Study Type

Observational

Enrollment (Actual)

7

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Lower Saxony
      • Hannover, Lower Saxony, Germany, 30625
        • Pediatric Surgery department

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

4 weeks to 5 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Children with newly and preoperatively diagnosed infantile Biliary Atresia of the non-syndromatic form

Description

Inclusion Criteria:

  • Non-Syndromatic Form of Biliary Atresia

Exclusion Criteria:

  • Syndromatic Form of Biliary Atresia
  • Other Congenital Liver Disease (Like Alagilles' Syndrome)
  • No liver fibrosis/cirrhosis in Histology of LIver Specimen from Routine Histology

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
MG Main Group
lymph node and blood sampling

By bipolar dissection 1 portal and 1 mesenteric lymph node are removed from the infant.

Blood (1ml) is taken from mother and infant.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maternal DNA in offspring
Time Frame: 3 months
The presence of maternal DNA in the childs blood and lymph nodes is the endpoint
3 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Serum Bilirubin
Time Frame: perioperatively
perioperatively
Composition of lymphocyte population in mesenteric lymph nodes
Time Frame: 3 months
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Carsten R Engelmann, MD, OhD, Klinikum Brandenburg

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2012

Primary Completion (Actual)

November 1, 2013

Study Completion (Actual)

November 1, 2014

Study Registration Dates

First Submitted

November 13, 2014

First Submitted That Met QC Criteria

November 14, 2014

First Posted (Estimate)

November 17, 2014

Study Record Updates

Last Update Posted (Estimate)

November 17, 2014

Last Update Submitted That Met QC Criteria

November 14, 2014

Last Verified

November 1, 2014

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Biliary Atresia

Clinical Trials on Lymph node and blood sampling

3
Subscribe